With NBS only having a market cap of around $115 million it is probably considered too speculative for most institutional investors and many won't touch a stock under a couple of bucks unless those investors are specifically looking for speculative stocks.
I think NBS has a lot going for it and I especially like how they are playing both sides, developing their own therapies and generating revenue by offering services to other companies. That's smart.
Looking at the graph, it seems to me that the 200 ma is .63 or .62 (between there). the 50ma is way down so no golden cross for awhile. but for the love of 2 cents, we'll cross the 200.
So the question: why the run up now ? was it the analyst coming on board with the reccomendations ? I can't beleive it's that.
It definitely was the analyst in my opinion. Analyst carry a bit more weight than SA article writers as it is their job to study and analyze and report to their constituencies with recommendations. They must retain credibility or lose their following.